Since anti-IL-23 is currently FDA approved for the treatment of other pro-inflammatory diseases, we believe our studies will open avenues for the development of promising strategies against the development and treatment of NAFLD. This evidence concerns the gene IL23A and metabolic dysfunction-associated steatotic liver disease.